Results 221 to 230 of about 12,578,124 (406)
THE ELIMINATION OF CHOLIC ACIDS. IV. IN PATIENTS WITH LIVER DISEASES 1 [PDF]
Bertil Josephson
openalex +1 more source
In prostate carcinoma, lactic acid, secreted by highly glycolytic cancer‐associated fibroblasts, is imported into tumor cells through the MCT1 transporter and prevents RSL3 and erastin‐induced ferroptosis (A). Targeting of carbonic anhydrase IX/XII, the main extracellular pH regulators, in tumor and stromal cells reduces microenvironmental acidosis and
Elisa Pardella+18 more
wiley +1 more source
This study presents a novel AI‐based diagnostic approach—comprehensive serum glycopeptide spectra analysis (CSGSA)—that integrates tumor markers and enriched glycopeptides from serum. Using a neural network model, this method accurately distinguishes liver and pancreatic cancers from healthy individuals.
Motoyuki Kohjima+6 more
wiley +1 more source
Glucose-6-Phosphatase of the Liver in Glycogen Storage Disease
Gerty T. Cori, Carl F. Cori
openalex +1 more source
Observations on the Curative Effect of Nicotinic Acid and of Liver in the Canine Black Tongue Disease1 [PDF]
R Nicolaysen, Per Laland
openalex +1 more source
Inflammation in Liver Diseases [PDF]
Dechun Feng+3 more
openaire +4 more sources
The tumor microenvironment is a dynamic, multifaceted complex system of interdependent cellular, biochemical, and biophysical components. Three‐dimensional in vitro models of the tumor microenvironment enable a better understanding of these interactions and their impact on cancer progression and therapeutic resistance.
Salma T. Rafik+3 more
wiley +1 more source
Liver‐specific knockout of N6‐methyladenosine (m6A) methyltransferase METTL3 significantly accelerated hepatic tumor initiation under various oncogenic challenges, contrary to the previously reported oncogenic role of METTL3 in liver cancer cell lines or xenograft models. Mechanistically, METTL3 deficiency reduced m6A deposition on Manf transcripts and
Bo Cui+15 more
wiley +1 more source
The A3 adenosine receptors (A3ARs) are overexpressed in prostate cancer. AR 292 and AR 357, as A3AR antagonists, are capable of blocking proliferation, modulating the expression of drug transporter genes involved in chemoresistance, ferroptosis, and the hypoxia response, and inducing cell death.
Maria Beatrice Morelli+15 more
wiley +1 more source